CaseVuPrecipio’s Blood Cancer Test Menu
Precipio’s cutting-edge blood cancer testing is focused on diagnostic accuracy and elevating patient care. Our commitment to innovation is evident in every aspect of our testing process, leveraging proprietary technology and aligning with the latest NCCN clinical guidelines. This ensures that our tests establish a gold standard for accuracy, making Precipio’s testing an invaluable resource for clinicians navigating the complexities of blood cancer diagnoses.
Part of Precipio’s approach is the integration of the Omnia Process, our methodology that combines hematopathology expertise with our proprietary technologies. This triaged approach to case workups ensures that the diagnostic journey begins with utmost accuracy, setting the stage for an efficient diagnostic process.
Blood Cancer Tests
Flow Cytometry
|
|
|
|
|---|---|---|---|
Leukemia/Lymphoma/MDS Screening Panel | or Peripheral Blood | or EDTA (Lavender Top) | |
| High Sensitivity PNH |
Histology
|
|
|
|
|---|---|---|---|
| Smear Morphology | |||
| Special Stains: (Giemsa, Iron, PAS, Reticulin, Congo Red, Trichrome, AFB, GMS) Bone Marrow Workup (H&E, Special Stains: Giemsa, Iron, PAS, Reticulin) | Blood Clot FFPE Tissue (Paraffin Block) | ||
| Immunohistochemistry: ALK1, Annexin A1, BCL1(CCND1), BCL2, BCL6, BOB.1, Calretinin, CD10, CD103, CD117, CD138, CD14, CD15, CD19, CD20, CD71, CD1a, CD2, CD21, CD25, CD3, CD30, CD34, CD38, CD4, CD43, CD45(LCA), CD5, CD56, CD61, CD68, CD79a, CD8, CDX2, CK20, CK5/6, C-Myc, EBER, ECadherin, Fascin, Glycophorin A, IgA, IgG, IgM, ISH, Kappa ISH, Ki-67, Lambda ISH, Lysozyme, MCT(Tryptase), MPO, MUM1, Oct2, PAX-5, PCK(AE1/AE3), Vimentin, WT1 | Blood Clot FFPE Tissue (Paraffin Block) | ||
Cytogenetics-Karyotyping
|
|
|
|
|---|---|---|---|
| Chromosome Analysis | or Peripheral Blood* |
* AML or CLL only
Cytogenetics-FISH
|
|
|
|
|
|---|---|---|---|---|
| MDS | MECOM/RPN1, 5q, 7q, Cep8/D20S108, MLL, ETV6, RARA, 19 | or Peripheral Blood | (Green Top) or EDTA (Lavendar Top) | |
| AML | RUNX1T1:RUNX1, PML::RARA, MLL, CBFB | |||
| AML & MDS combined | RUNX1T1::RUNX1, MLL, PML::RARA, CBFB, 5q, 7q, Cep8/D20S108, MECOM/RPN1 | |||
| MPN, PV, ET, Eosinophilia, Neutropenia | PDGFRA, PDGFRB, FGFR1/Cep8, BCR::ABL, 19 | |||
| CML | BCR::ABL |
|||
| MPD | 5q, 7q, Cep8/D20S108, BCR::ABL, ETV6, MLL | |||
| Myeloma | 1p36, p53/CEP9, CCND1::IGH, D13S319, MYC::IGH | |||
| Extended Myeloma | FGFR3::IGH, IGH::MAF | |||
| CLL | CCND1::IGH, ATM/p53, Cep12/13q34/13q14.3, MYC::IGH | |||
| LPD, NHL, MZL, FL, MALT, Burkitt, NCL, DLBCL | BCL6, 7q, MYC::IGH, CCND1::IGH, BIRC3::MALT1, IGH::BCL2, MLL, p53/CEP9 |
|||
| LPL | 5q, MYB (6q), CCND1::IGH t(11;14), MYC::IGH t(8;14), FGFR3::IGH t(4;14) | |||
| T-Cell Lymphoma & ALL | 1p36, Cep8/D20S108, BCR::ABL, ETV6::RUNX1, MLL, IGH | |||
| APL | PML::RARA |
Molecular
|
|
|
|
|---|---|---|---|
| IgVH | or Peripheral Blood | (Lavender Top) | PB: 4ml |
| B-Cell Gene Rearrangement | |||
| Bloodhound™ BCR::ABL1 (p.190, p.203, p.210, p.230) w/ABL1 Reflex | |||
| T-Cell Gene Rearrangement | |||
| Bloodhound™ for MPN (JAK2 Exons 12, 13, 14 (V617F), CALR, MPL) | or Peripheral Blood | (Green Top) EDTA (Lavender Top) | |
| HemeScreen® for Cytopenia (ASXL1, WT1, DNMT3A (Exon 23), SF3B1) | |||
| HemeScreen® for AML (IDH1, IDH2, KIT, FLT3, NPM1, CEBPA) | |||
| HemeScreen® for CLL (SF3B1, CXCR4, MYD88, NOTCH1) |
NGS
|
|
|
|
|---|---|---|---|
| NGS Hematologis Malignancies Panel | or Peripheral Blood | (Lavender Top) |
|
||||
|---|---|---|---|---|
| ABL1 | ANKRD26 | ASXL1 | BCOR• | ATRX |
| BCORL1• | BRAF | CALR | CBLB | CBL |
| CBLC | CDKN2A• | CEBPA• | CUX1 | CSF3R |
| DDX41 | DNMT3A• | ETNK1 | ETV6• | EZH2• |
| FLT3 | GATA1 | GATA2• | GNAS | HRAS |
| IDH1 | IDH2 | IKZF1• | JAK3 | JAK2 |
| KDM6A• | KIT | KMT2A | MPL | KRAS |
| NF1 | NPM1 | NRAS | PHF6• | PDGFRA |
| PIGA• | PPMID | PTEN | RAD21• | PTPN11 |
| RUNX1• | SETBP1 | SF3B1 | SMC3 | SMC1A |
| SRSF2 | STAG• | STAG1 | TP53• | TET2• |
| U2AF1 | WT1 | ZRSR2• | ||
• Indicated full CDS coverage in gene